14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
PACB vs MXCT: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, MaxCyte, Inc. (MXCT) is the stronger overall head-to-head candidate over Pacific Biosciences of California, Inc. (PACB) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). PACB carries a Unified Composite Score of 50.1/100 (HOLD) at $1.63 (N/M Forward P/E, -333.0% operating margin), whereas MXCT carries 41.7/100 (SELL) at $1.37 (N/M Forward P/E, -85.5% operating margin).
Composite vs. Pillar Nuance: While PACB currently prints a higher short-term Unified Composite Score (50.1/100 HOLD vs. MXCT 41.7/100 SELL), MXCT captures the overall institutional head-to-head verdict (5–2 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-85.5% vs. -333.0% operating margin) and revenue trajectory (+48.7% vs. +5.5% YoY).
Technical & Structure Timing Caution: PACB is currently in a Breakdown options structure phase (RSI 35.4); meanwhile MXCT trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 55.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Medical Devices value chain with $132.2M market capitalization and -85.5% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ PACB vs MXCT Key Questions & Quantitative Answers
As of Nov 20, 2026, MaxCyte, Inc. (MXCT) is the stronger overall head-to-head candidate over Pacific Biosciences of California, Inc. (PACB) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). PACB carries a Unified Composite Score of 50.1/100 (HOLD) at $1.63 (N/M Forward P/E, -333.0% operating margin), whereas MXCT carries 41.7/100 (SELL) at $1.37 (N/M Forward P/E, -85.5% operating margin). Composite vs. Pillar Nuance: While PACB currently prints a higher short-term Unified Composite Score (50.1/100 HOLD vs. MXCT 41.7/100 SELL), MXCT captures the overall institutional head-to-head verdict (5–2 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-85.5% vs. -333.0% operating margin) and revenue trajectory (+48.7% vs. +5.5% YoY). Technical & Structure Timing Caution: PACB is currently in a Breakdown options structure phase (RSI 35.4); meanwhile MXCT trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 55.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
PACB leads the Growth & Scale pillar: PACB posts +5.5% YoY revenue growth and +0.0% YoY earnings growth on $161M TTM revenue (27.7% gross margin, -333.0% operating margin), compared with MXCT at +48.7% YoY revenue growth and +0.0% YoY earnings growth on $34M TTM revenue (81.0% gross margin, -85.5% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), PACB cumulative revenue shifted +100.0% while MXCT shifted +100.0%. In operating R&D and SG&A reinvestment, PACB deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MXCT.
MXCT screens cheaper on headline valuation multiples. PACB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 7.4x EV/Revenue (-93.2% FCF margin), whereas MXCT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.9x EV/Revenue (-69.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PACB (-929.3% ROE) versus MXCT (-16.9% ROE) capital efficiency.
In options market volatility and institutional positioning, PACB carries 191.0% implied volatility (97th %ile, Extreme (>80th %ile)), a 0.07x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.25β · 104% Vol realized risk). By comparison, MXCT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.19β · 96% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.